Global Percutaneous Vessel Closure Devices Market Strategic Research Report

Scope of the Report

The global Percutaneous Vessel Closure Devices market size is predicted to grow from US$ 1,491 million in 2025 to US$ 2,343 million in 2032; it is expected to grow at a CAGR of 6.8% from 2026 to 2032.

Percutaneous vessel closure devices (VCDs) are catheter-based systems designed to achieve hemostasis and seal the arteriotomy/venotomy after endovascular procedures—most commonly at femoral access sites, spanning standard 5–7F sheaths to large-bore access used in structural heart interventions. They employ mechanisms such as suture-mediated closure, collagen/bio-material plugs, extravascular sealants, or mechanical anchoring to reduce manual compression time and improve workflow reproducibility. FDA-cleared devices commonly position benefits around shorter time to hemostasis/ambulation, and dedicated large-bore closure systems have emerged for procedures such as TAVR. In 2025, global Percutaneous vessel closure devices production reached approximately 5.08 million units and price is about 300 USD/Unit.The average gross profit margin of this product is 65%.

Growth is driven by workflow industrialization of hemostasis management and the non-negotiable need for access efficiency in complex interventions. In femoral-dominant procedures (complex PCI, peripheral interventions, structural heart such as TAVR), providers prioritize predictable turnover, reduced nursing burden, and complication governance. Reviews and outcomes studies commonly associate VCD use with shorter time to hemostasis and ambulation, aligning with day-case and high-throughput operational goals. In parallel, large-bore closure demand is rising, making dedicated large-bore devices (e.g., MANTA) part of the structural-heart access ecosystem and shifting the category from “routine consumable” toward “standard configuration” in structural programs.

The constraint is not the concept of closure, but sensitivity to anatomy and vessel condition. Calcification burden, suboptimal puncture location, vessel size, and wall quality can affect device success and vascular complications—particularly in large-bore access for TAVR. Suture-mediated closure can improve efficiency yet still carries rare but high-impact events such as pseudoaneurysm and infection, increasing the importance of patient selection, ultrasound-guided access, post-procedure surveillance, and standardized training. From a governance standpoint, VCDs sit on a critical step in the procedure, making auditability, event traceability, and supply reliability decisive for scalable adoption.

Demand is shifting from “buying a closure device” to “access-management solutions.” Best-practice frameworks emphasize integrating ultrasound-guided access, micropuncture technique, anticoagulation strategy, and closure choice into a repeatable pathway—positioning VCDs as part of bleeding-avoidance strategies and pushing vendors toward bundled delivery of devices, training, and pathway tools. Meanwhile, expansion of large-bore structural interventions is accelerating parallel adoption of pre-close suture strategies and dedicated large-bore devices, with greater focus on imaging assessment, calcification stratification, and bail-out planning. Radial expansion may reduce portions of femoral closure volume in some markets, but large-bore and complex peripheral access will continue to structurally support VCD demand.

Upstream differentiation centers on bio-material sealing elements, precision delivery systems, and consistent manufacturability with visibility. Suture-mediated devices depend on high-strength medical sutures, needles, and delivery mechanics; collagen/bio-material plug devices depend on controlled-degradation materials, anchoring structures, and hemostatic interface design; large-bore devices emphasize biomechanical anchoring and sealing reliability under high-pressure femoral conditions. Catheter-grade polymers, radiopaque markers, lubricious coatings, sterile packaging, and validated sterilization determine batch consistency and deliverability, while regulatory and preclinical expectations around sealing reliability and vessel safety push supply chains toward integrated “quality systems + engineering validation + traceable delivery.”

Key Questions Addressed in this Report

What is the 10-year outlook for the global Percutaneous Vessel Closure Devices market?

What factors are driving Percutaneous Vessel Closure Devices market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Percutaneous Vessel Closure Devices market opportunities vary by end market size?

How does Percutaneous Vessel Closure Devices break out by Type, by Application?

This report presents a comprehensive overview of the global Percutaneous Vessel Closure Devices market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Suture-based Closure Devices
• Collagen Plug-based Devices
• Clip-based Closure Systems
• Sealant-based Closure Devices

Segment by Clinical Procedure

• Interventional Cardiology
• Peripheral Vascular Interventions
• Structural Heart Procedures
• Neurovascular Procedures

Segment by Access Site Type

• Femoral Artery
• Femoral Vein
• Radial Artery
• Other

Segment by Application

• Hospitals
• ASCs
• Online

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Percutaneous Vessel Closure Devices market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, ASCs, Online evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact